Hemab Therapeutics Holdings, Inc.Hemab Therapeutics Holdings, Inc.
COAGHealth Care·Biotechnology
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded on February 12, 2026 and is headquartered in Cambridge, MA.
Market cap
$1.4BNo data
Revenue
No dataNo data
Net income
No dataNo data
Free cash flow
No dataNo data
Ample short-term liquidity from substantial current assets versus liabilities supports near-term obligations, while capital deployed this quarter produced losses and weaker return on invested capital; operating margin is deeply negative.
As of 2026-06-30Market
Listed stock
COAGPriceNasdaqLoading…Loading…1Y